Angiogenesis: A special reference to corneal neovascularization

Ljubiša Nikolić; Vesna Jovanović

doi:10.2298/5081

Ljubiša Nikolić Faculty of Dentistry, University of Belgrade, Belgrade, Serbia; Oculus, Hospital for Eye Diseases, Belgrade, Serbia
Vesna Jovanović Faculty of Dentistry, University of Belgrade, Belgrade, Serbia; Department of Ophthalmology “Prof. Dr Ivan Stanković”, University Hospital “Zvezdara”, University of Belgrade, Belgrade, Serbia

DOI: https://doi.org/10.2298/5081

Keywords: corneal neovascularisation, neovascularisation, pathologic, drug therapy,

Author Biographies

Ljubiša Nikolić, Faculty of Dentistry, University of Belgrade, Belgrade, Serbia; Oculus, Hospital for Eye Diseases, Belgrade, Serbia

Chief, Ophthalmology

Vesna Jovanović, Faculty of Dentistry, University of Belgrade, Belgrade, Serbia; Department of Ophthalmology “Prof. Dr Ivan Stanković”, University Hospital “Zvezdara”, University of Belgrade, Belgrade, Serbia

Ophthalmology, Assistant Pofessor

References

Hertig AT. Angiogenesis in the early human chorion and in the placenta of the macaque monkey. Contrib Embryol Carnegie Inst 1935; 25(146): 37−81.

Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267(16): 10931−4.

Algire GH. Microscopic studies of the early growth of a trans-plantable melanoma of the mouse, using the transparent-chamber technique. J Natl Cancer Inst 1943; 4(1): 13−20.

Michaelson IC. The mode of development of the vascular sys-tem of the retina with some observations on its significance in certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137−80.

Folkman J, Long D, Becker FF. Growth and metastasis of tumor in organ culture. Cancer 1963; 16: 452−67.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182−6.

Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133(2): 275−88.

Nikolic Lj. Angiogenesis. In: Nikolic Lj, Danjo S, editors. Diabetic retinopathy. Beograd: Zavod za udžbenike i nastavna sredstva; 1999. p. 75−98. (Serbian)

Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003; 49(1): 32−40.

Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987; 329(6141): 671−2.

Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235(4787): 442−7.

Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982; 297(5864): 307−12.

Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221(4612): 719−25.

Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230(4732): 1375−8.

Nikolic L, Friend J, Taylor S, Thoft RA. Inhibition of vasculariza-tion in rabbit corneas by heparin: cortisone pellets. Invest Ophthalmol Vis Sci 1986; 27(4): 449−56.

O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79(2): 315−28.

O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277−85.

Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029−39.

Ferrara N, Gerber H, le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669−76.

Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1(2): 182−93.

Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266(18): 11947−54.

Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006; 10(4): 515−27.

D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007; 171(1): 14−8.

Ljubimov AJ. Growth factor synergy in angiogenesis. In: Penn JS, editor. Retinal and choroidal angiogenesis. Dordrecht, Nederlands: Springer; 2008. p. 289−310.

Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32(2): 115−20.

Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009; 247(6): 767−73.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353(8): 782−92.

Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145−82.

Kwanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006; 84(3): 282−8.

Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843−5.

Balsara RD, Merryman R, Virjee F, Northway C, Castellino FJ, Plop-lis VA. A deficiency of uPAR alters endothelial angiogenic function and cell morphology. Vascular Cell 2011; 3(1): 10.

Singhvi R, Kumar A, Lopez GP, Stephanopoulos GN, Wang DI, Whitesides GM, et al. Engineering cell shape and function. Science 1994; 264(5159): 696−8.

Ingber DE. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc Natl Acad Sci U S A 1990; 87(9): 3579−83.

Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol 1988; 130(2): 393−400.

Nikolic LB. Angiogenesis in rabbit cornea after disruption of descemet's membrane in the presence of heparin. Vestn Of-talmol 1998; 114(4): 35−8.

Wang F, Sloss C, Zhang X, Lee SW, Cusack JC. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 2007; 67(18): 8486−93.

Speiser P, Gittelsohn AM, Patz A. Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968; 80(3): 332−7.

Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987; 105(3): 1455−62.

Ramsauer M, D'Amore PA. Getting Tie(2)d up in angiogenesis. J Clin Invest 2002; 110(11): 1615−7.

Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in an-giogenesis. Cell Tissue Res 2003; 314(1): 15−23.

Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265(5178): 1582−4.

Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble re-ceptor. Proc Natl Acad Sci U S A 1993; 90(22): 10705−9.

Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16(2): 196−208.

Pepper MS. Role of the matrix metalloproteinase and plasmino-gen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21(7): 1104−17.

Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339(1): 269−80.

Nikolic LJ. Experimental keratoplasty: a model for corneal vascularization research. Srp Arh Celok Lek 1986; 113: 135−44.

Cogan D. Corneal vascularization. Invest Ophthalmol 1962;1 :253−61.

Cogan DG. Vascularization of the cornea: its experimental in-duction by small lesions and a new theory of its pathogenesis. Arch Ophthalmol 1949; 41(4): 406−16.

Campbell FW, Michaelson IC. Blood-vessel formation in the cornea. Br J Ophthalmol 1949; 33(4): 248−55.

Ashton N, Cook C. Mechanism of corneal vascularization. Br J Ophthalmol 1953; 37(4): 193−209.

Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443(7114): 993−7.

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006; 103(30): 11405−10.

Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, et al. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem 2008; 283(49): 34250−9.

Han Y, Shao Y, Lin Z, Qu Y, Wang H, Zhou Y, et al. Netrin-1 simultaneously suppresses corneal inflammation and neovascularization. Invest Ophthalmol Vis Sci 2012; 53(3): 1285−95.

Davanger M, Evensen A. Role of the pericorneal papillary struc-ture in renewal of corneal epithelium. Nature 1971; 229(5286): 560−1.

Ebato B, Friend J, Thoft RA. Comparison of central and peripheral human corneal epithelium in tissue culture. Invest Ophthalmol Vis Sci 1987; 28(9): 1450−6.

Ti S, Grueterich M, Espana EM, Touhami A, Anderson DF, Tseng SC. Correlation of long term phenotypic and clinical outcomes following limbal epithelial transplantation cultivated on amniotic membrane in rabbits. Br J Ophthalmol 2004; 88(3): 422−7.

Armstrong DJ, Hiscott P, Batterbury M, Kaye S. Corneal stromal cells (keratocytes) express thrombospondins 2 and 3 in wound repair phenotype. Int J Biochem Cell Biol 2002; 34(6): 588−93.

Sekiyama E, Nakamura T, Cooper LJ, Kawasaki S, Hamuro J, Full-wood NJ, et al. Unique distribution of thrombospondin-1 in human ocular surface epithelium. Invest Ophthalmol Vis Sci 2006; 47(4): 1352−8.

Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264−302.

Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006; 281(6): 3604−13.

Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86(1): 346−55.

Khamis ZI, Zorio DA, Chung LW, Sang QA. The Anti-inflammatory Role of Endometase/Matrilysin-2 in Human Prostate Cancer Cells. J Cancer 2013; 4(4): 296−303.

Mann I, Pirie A, Pullinger BD. An experimental and clinical study of the reaction of the anterior segment of the eye to chemical injury, with special reference to chemical warfare agents. Br J Ophthalmol 1948; 13(Suppl): 171.

Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthamol 2001; 12(4): 242−9.

Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43(3): 245−69.

Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 2012; 57(5): 448−62.

Philipp W, Speicher L, Humpel C. Expression of vascular endo-thelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41(9): 2514−22. 69.

Stevenson W, Cheng S, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 2012; 10(2): 67−83.

Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012; 181(2): 376−9.

Hajrasouliha AR, Sadrai Z, Chauhan SK, Dana R. b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea 2012; 31(7): 804−9.

Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005; 7(9): 870−9.

Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, et al. Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A 2013; 110(33): 13528−33.

Haynes RC, Murad F. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: Macmillan Publishing Company; 1985. p. 1459−89.

Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986; 119(4): 1768−75.

Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992; 10(3): 505−12.

Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract devel-opment among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117(7): 1436−41.

Bremer F. Origin of corticosteroid glaucoma. Bull Soc Belge Ophtalmol 2007; (304): 111−6. (French)

Sheppard JD, Epstein RJ, Lattanzio FA, Marcantonio D, Williams PB. Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether. Am J Ophthalmol 2006; 141(3): 524−9.

Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000; 41(8): 2148−53.

Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994; 101(9): 1536−47.

Takahashi K, Saishin Y, Saishin Y, Mori K, Ando A, Yamamoto S, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003; 44(1): 409−15.

Zanini M, Savini G, Barboni P. Corneal melting associated with topical diclofenac use after laser-assisted subepithelial keratectomy. J Cataract Refract Surg 2006; 32(9): 1570−2.

Asai T, Nakagami T, Mochizuki M, Hata N, Tsuchiya T, Hotta Y. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006; 25(2): 224−7.

Moisseiev E, Varssano D. Comparison of Ocular Tolerability Be-tween Preserved and Preservative-Free Diclofenac Sodium Drops. J Ocul Pharmacol Ther 2011; 27(4): 333−7.

Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992; 110(3): 405−7.

Joussen AM, Kruse FE, Völcker HE, Kirchhof B. Topical applica-tion of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999; 237(11): 920−7.

Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the man-agement of high-risk corneal and limbal grafts. Ophthalmology 2001; 108(10): 1838−44.

D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91(6): 4082−5.

McBride WG. Thalidomide and congenital anomalies. Lancet 1961; 2: 1358.

Parentin F, da Pozzo S, Lepore L, Perissutti P. Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child. Ophthalmologica 2001; 215(1): 70−3.

Avery RL, Connor TB, Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol 1990; 108(10): 1474−6.

Ignjatović Z, Nikolić L. Inhibition of angiogenesis in the cornea with amiloride. Srp Arh Celok Lek 1996; 124(5-6): 120−3. (Serbian)

Papathanassiou M, Theodoropoulou S, Analitis A, Tzonou A, Theodossiadis PG. Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis. Cornea 2013; 32(4): 435−44.

Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, et al. . Forty-year journey of angiogenesis translational research. Sci Transl Med 2011; 114(3): 114rv3.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335−42.

Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28(11): 1779−802.

Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treat-ment of ocular disease. Surv Ophthalmol 2009; 54(3): 372−400.

Ristic D, Vukosavljevic M, Draganic B, Cerovic V, Petrovic N, Janicijevic-Petrovic M. The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation. Vojnosanit Pregl 2013; 70(7): 660−3.

Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Renet M, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007; 91(6): 804−7.

de Stefano J, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125(6): 834−6.

Bock F, Koenig Y, Kruse F, Baier M, Cursifen C. Bevacizu-mab(Avastin) eye drops inhibit corneal neovacularization. Graefes Arch Clin Exp Ophthalmol 2008; 246(2): 281−4.

Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115(6): e33−8.

Dastherdi MH, Al-Arafaj KM, Nallasany N, Pineda R, Pavan-Langston D, Dana R. Topical bevacizumab in the treatment of corneal neovascularization; results of a prospective, open-label, non-comparative study. Arch Ophthalmol 2009; 127(4): 381−9.

Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, et al. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol 2012; 154(6): 940−8e1.

Young SN, Lichtinger A, Kim P, Mohammadpour M. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011; 30(10): 1110−4.

Ferrari G, Dastjerdi MH, Okanobo A, Cheng S, Amparo F, Nalla-samy N, et al. Topical ranibizumab as a treatment of corneal neovascularization. Cornea 2013; 32(7): 992−7.

Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK. Bevacizu-mab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009; 50(10): 4653−9.

Kim EC, Ryu HW, Lee HJ, Kim MS. Bevacizumab eye drops de-lay corneal epithelial wound healing and increase the stromal response to epithelial injury in rats. Clin Experiment Ophthalmol 2013; 41(7): 694−701.

Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevaci-zumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247(10): 1375−82.

Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye 2008; 22(10): 1330−6.

Oliveira HB, Sakimoto T, Javier JA, Azar DT, Wiegand SJ, Jain S, et al. VEGF Trap (R1R2) suppresses experimental corneal angiogenesis. Eur J Ophthalmol 2010; 20(1): 48−54.

Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol 2013; 6(2): 103−13.

Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4(6): 457−67.

Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008; 49(5): 1836−42.

Kim JW, Chung SK. The effect of topical infliximab on corneal neovascularization in rabbits. Cornea 2013; 32(2): 185−90.

Moses MA, Harper J, Folkman J. Doxycycline treatment for lym-phangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006; 354(24): 2621−2.

Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12(2): 12−26.

Cerisano G, Buonamici P, Valenti R, Sciagrà R, Raspanti S, Santini A, et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J 2014; 35(3): 184−91.

Malik YS, Sheikh MA, Zhu X. Doxycycline can stimulate cytoprotection in neural stem cells with oxygen-glucose deprivation-reoxygenation injury: a potential approach to enhance effectiveness of cell transplantation therapy. Biochem Biophys Res Commun 2013; 432(2): 355−8.

Aydin E, Kivilcim M, Peyman GA, Esfahani MR, Kazi AA, Sanders DR. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 2008; 27(4): 446−53.

Jovanovic V, Nikolic L. The effect of topical doxycycline on corneal neovascularization. Curr Eye Res 2014; 39(2): 142−8.

Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995; 36(5): 418−24.

Su W, Li Z, Li Y, Lin M, Yao L, Liu Y, et al. Doxycycline en-hances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects. Invest Ophthalmol Vis Sci 2011; 52(12): 9108−15.